PA8633101A1 - ACID 2 - {[2- (2-METHYLAMINE-PYRIMIDIN-4-IL) -1H-INDOL-5-CARBONIL] -AMINO} -3- (PHENYLPIRIDIN-2-IL-AMINO) SUBSTANTIALLY PURE PROPIONIC AS IKB KINASE INHIBITOR - Google Patents

ACID 2 - {[2- (2-METHYLAMINE-PYRIMIDIN-4-IL) -1H-INDOL-5-CARBONIL] -AMINO} -3- (PHENYLPIRIDIN-2-IL-AMINO) SUBSTANTIALLY PURE PROPIONIC AS IKB KINASE INHIBITOR

Info

Publication number
PA8633101A1
PA8633101A1 PA20058633101A PA8633101A PA8633101A1 PA 8633101 A1 PA8633101 A1 PA 8633101A1 PA 20058633101 A PA20058633101 A PA 20058633101A PA 8633101 A PA8633101 A PA 8633101A PA 8633101 A1 PA8633101 A1 PA 8633101A1
Authority
PA
Panama
Prior art keywords
amino
substantially pure
phenylpiridin
carbonil
indol
Prior art date
Application number
PA20058633101A
Other languages
Spanish (es)
Inventor
Paul Joseph Cox
Olaf Ritzeler
Haddad El-Bdaoui
David J Aldous
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of PA8633101A1 publication Critical patent/PA8633101A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION ESTA DIRIGIDA AL COMPUESTO SUSTANCIALMENTE PURO DE FORMULA (A), O UNA SAL FARMACEUTICAMENTE ACEPTABLE, O SOLVATO DE DICHO COMPUESTO; A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UNA CANTIDAD FARMACEUTICAMENTE EFICAZ DEL COMPUESTO DE FORMULA (A), Y UN VEHICULO FARMACEUTICAMENTE ACEPTABLE; Y AL USO DE UN COMPUESTO DE FORMULA (A) QUE TIENE ACTIVIDAD COMO INHIBIDOR, PREFERIBLEMENTE UN INHIBIDOR SELECTIVO DE IKB (IKK), EN PARTICULAR IKK-2, Y A METODOS RELACIONADOS CON ELLO.THIS INVENTION IS DIRECTED TO THE SUBSTANTIALLY PURE COMPOUND OF FORMULA (A), OR A PHARMACEUTICALLY ACCEPTABLE SALT, OR SOLVATE OF SUCH COMPOUND; TO A PHARMACEUTICAL COMPOSITION THAT INCLUDES A PHARMACEUTICALLY EFFECTIVE AMOUNT OF THE FORMULA COMPOUND (A), AND A PHARMACEUTICALLY ACCEPTABLE VEHICLE; AND TO THE USE OF A FORMULA COMPOUND (A) THAT HAS ACTIVITY AS AN INHIBITOR, PREFERIBLY A SELECTIVE IKB INHIBITOR (IKK), IN PARTICULAR IKK-2, AND TO METHODS RELATED TO IT.

PA20058633101A 2004-05-12 2005-05-12 ACID 2 - {[2- (2-METHYLAMINE-PYRIMIDIN-4-IL) -1H-INDOL-5-CARBONIL] -AMINO} -3- (PHENYLPIRIDIN-2-IL-AMINO) SUBSTANTIALLY PURE PROPIONIC AS IKB KINASE INHIBITOR PA8633101A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57014604P 2004-05-12 2004-05-12

Publications (1)

Publication Number Publication Date
PA8633101A1 true PA8633101A1 (en) 2006-01-23

Family

ID=34969825

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20058633101A PA8633101A1 (en) 2004-05-12 2005-05-12 ACID 2 - {[2- (2-METHYLAMINE-PYRIMIDIN-4-IL) -1H-INDOL-5-CARBONIL] -AMINO} -3- (PHENYLPIRIDIN-2-IL-AMINO) SUBSTANTIALLY PURE PROPIONIC AS IKB KINASE INHIBITOR

Country Status (23)

Country Link
EP (1) EP1747215A1 (en)
JP (1) JP2007537266A (en)
KR (1) KR20070011483A (en)
CN (1) CN1950359A (en)
AR (1) AR049274A1 (en)
AU (1) AU2005245834A1 (en)
BR (1) BRPI0511029A (en)
CA (1) CA2566213A1 (en)
EC (1) ECSP066992A (en)
GT (1) GT200500111A (en)
IL (1) IL178992A0 (en)
MA (1) MA28553B1 (en)
MX (1) MXPA06012870A (en)
NO (1) NO20065719L (en)
PA (1) PA8633101A1 (en)
PE (1) PE20060269A1 (en)
RU (1) RU2006143758A (en)
SV (1) SV2006002111A (en)
TN (1) TNSN06338A1 (en)
TW (1) TW200605881A (en)
UY (1) UY28897A1 (en)
WO (1) WO2005113544A1 (en)
ZA (1) ZA200608712B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19951360A1 (en) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituted indoles
DE102004033406A1 (en) * 2004-07-10 2006-02-16 Sanofi-Aventis Deutschland Gmbh Process for the preparation of the enantiomeric forms of 2,3-diaminopropionic acid derivatives
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
CA2721927C (en) 2008-04-21 2014-01-28 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
EP2563774B1 (en) * 2010-04-27 2014-03-12 Hutchison Medipharma Limited Pyrimidinyl indole compounds
EP2582709B1 (en) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (en) 2011-03-08 2016-06-01 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CA3029281A1 (en) 2016-06-29 2018-01-04 Otonomy, Inc. Triglyceride otic formulations and uses thereof
CN106588803A (en) * 2016-11-16 2017-04-26 西南科技大学 Novel method for preparing 5-acetylisoxazole

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10237722A1 (en) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indole or benzimidazole derivatives for the modulation of IKappaB kinase

Also Published As

Publication number Publication date
IL178992A0 (en) 2007-03-08
RU2006143758A (en) 2008-06-27
WO2005113544A1 (en) 2005-12-01
ZA200608712B (en) 2008-06-25
BRPI0511029A (en) 2007-11-27
UY28897A1 (en) 2005-12-30
PE20060269A1 (en) 2006-05-11
AU2005245834A1 (en) 2005-12-01
ECSP066992A (en) 2006-12-29
TW200605881A (en) 2006-02-16
AR049274A1 (en) 2006-07-12
KR20070011483A (en) 2007-01-24
MXPA06012870A (en) 2007-02-15
NO20065719L (en) 2006-12-12
JP2007537266A (en) 2007-12-20
GT200500111A (en) 2006-05-09
CA2566213A1 (en) 2005-12-11
EP1747215A1 (en) 2007-01-31
SV2006002111A (en) 2006-01-30
MA28553B1 (en) 2007-04-03
CN1950359A (en) 2007-04-18
TNSN06338A1 (en) 2008-02-22

Similar Documents

Publication Publication Date Title
PA8633101A1 (en) ACID 2 - {[2- (2-METHYLAMINE-PYRIMIDIN-4-IL) -1H-INDOL-5-CARBONIL] -AMINO} -3- (PHENYLPIRIDIN-2-IL-AMINO) SUBSTANTIALLY PURE PROPIONIC AS IKB KINASE INHIBITOR
AR062797A1 (en) PIPERIDINE DERIVATIVES AS RENINE INHIBITORS, PHARMACEUTICAL COMPOSITIONS.
HN2009000792A (en) HCV PROTEASA NS3 INHIBITORS
ECSP088258A (en) SERINA PROTEASAS INHIBITORS
UY30941A1 (en) SERINA PROTEASAS INHIBITORS
HN2011000874A (en) INHIBITORS OF PROTEIN CINASE ENZYMES ACTIVATED BY MYTHOGEN P38
WO2006133147A3 (en) Organic compounds
CO6231036A2 (en) SULFUR COMPOUNDS AS INHIBITORS OF THE SERINA PROTEASA NS3 OF THE HEPATITIS C VIRUS
HN2008000134A (en) MACROCICLIC INHIBITORS OF VIRUS HEPATITIS C
RS52903B (en) Benzofuranyl derivatives used as glucokinase inhibitors
CR11252A (en) NEW DERIVATIVES OF 6-TRIAZOLOPIRIDACINA-SULFANIL BENZOTIAZOL AND BENCIMIDAZOL, ITS PREPARATION PROCEDURE, ITS APPLICATION AS MEDICATIONS, PHARMACEUTICAL COMPOSITIONS AND NEW MAIN USE AS MET INHIBITORS
NO20074544L (en) Inhibition of HER2 release by matrix metalloprotease antagonists
CL2007003540A1 (en) COMPOUNDS DERIVED FROM MACROCICLES, INHIBITORS OF THE SERINE PROTEASE OF HEPATITIS C; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF HEPATITIS C.
UY31736A (en) SUBSTITUTED DERIVATIVES OF PIRAZOL AND ITS USE
BRPI0408353A (en) compound, pharmaceutical composition, methods for the treatment of susceptible neoplasms and for the treatment of viral infections, and, use of a compound
ECSP088965A (en) 2-THIOXANTINE DERIVATIVES THAT ACT AS INHIBITORS OF THE MPO
GT200900192A (en) IMIDAZOL DERIVATIVES AS PROTEIN INHIBITORS FOR THE USE OF CINESINE (EG-5) .-
SV2006002274A (en) DERIVATIVES OF 2-AMIDO-4-PHENYLTIAZOL, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
NO20084547L (en) Process for Preparation of HIV Protease Inhibitors
HN2003000044A (en) ESTERES HYDROXAMATE OF ACID N - (4-PHENYL REPLACED) -ANTRANILICO.
AR057909A1 (en) PROCESS TO PREPARE MONTELUKAST AND RELATED COMPOUNDS, USING AN INTERMEDIATE COMPOUND DERIVED FROM A SULFONIC ESTER.
EA200801145A1 (en) SPYROCYCLIC DERIVATIVES OF HINAZOLIN AS PDE7 INHIBITORS
DK1856063T3 (en) 5-PHENYL PENTANIC ACID DERIVATIVES AS MATRIX-METALOPROTEINASE INHIBITORS FOR THE TREATMENT OF ASTMA AND OTHER DISEASES
MY146671A (en) Tetrahydronaphthaline derivatives, methods for the production and use thereof as anti-inflammatory agents
PA8661701A1 (en) THIAZOLIDINONES, ITS PREPARATION AND ITS USE AS A MEDICINAL PRODUCT